deltatrials
Active Not Recruiting OBSERVATIONAL NCT04871919

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis (FILOSOPHY)

A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib

Sponsor: Alfasigma S.p.A.

Conditions Rheumatoid Arthritis
Interventions Filgotinib
Updated 27 times since 2021 Last updated: Sep 9, 2025 Started: May 11, 2021 Primary completion: Jun 30, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Rheumatoid Arthritis and is currently ongoing. Alfasigma S.p.A. leads this study, which shows 27 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Feb 2024 · 9 months · monthly snapshot~Feb 2024 – ~May 2024 · 3 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

27 versions recorded

  1. Oct 2025 — Present [monthly]

    Active Not Recruiting

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting

  3. Jan 2025 — Sep 2025 [monthly]

    Active Not Recruiting

  4. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting

▶ Show 22 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  3. May 2024 — Jun 2024 [monthly]

    Recruiting

  4. Feb 2024 — May 2024 [monthly]

    Recruiting

  5. May 2023 — Feb 2024 [monthly]

    Recruiting

  6. Mar 2023 — May 2023 [monthly]

    Recruiting

  7. Feb 2023 — Mar 2023 [monthly]

    Recruiting

  8. Jan 2023 — Feb 2023 [monthly]

    Recruiting

  9. Nov 2022 — Jan 2023 [monthly]

    Recruiting

  10. Sep 2022 — Nov 2022 [monthly]

    Recruiting

  11. Jul 2022 — Sep 2022 [monthly]

    Recruiting

  12. Jun 2022 — Jul 2022 [monthly]

    Recruiting

  13. May 2022 — Jun 2022 [monthly]

    Recruiting

  14. Apr 2022 — May 2022 [monthly]

    Recruiting

  15. Mar 2022 — Apr 2022 [monthly]

    Recruiting

  16. Feb 2022 — Mar 2022 [monthly]

    Recruiting

  17. Jan 2022 — Feb 2022 [monthly]

    Recruiting

  18. Dec 2021 — Jan 2022 [monthly]

    Recruiting

  19. Nov 2021 — Dec 2021 [monthly]

    Recruiting

  20. Oct 2021 — Nov 2021 [monthly]

    Recruiting

  21. Sep 2021 — Oct 2021 [monthly]

    Recruiting

  22. Jun 2021 — Sep 2021 [monthly]

    Recruiting

    First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alfasigma S.p.A.
Data source: Alfasigma S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Aberdeen, United Kingdom , Alkmaar, Netherlands , Altenburg, Germany , Amberg, Germany , Amsterdam, Netherlands , Bad Doberan, Germany , Barcelona, Spain , Bari, Italy and 67 more locations